HRP20161503T1 - Novi oblici cddo metilnog estera - Google Patents
Novi oblici cddo metilnog estera Download PDFInfo
- Publication number
- HRP20161503T1 HRP20161503T1 HRP20161503TT HRP20161503T HRP20161503T1 HR P20161503 T1 HRP20161503 T1 HR P20161503T1 HR P20161503T T HRP20161503T T HR P20161503TT HR P20161503 T HRP20161503 T HR P20161503T HR P20161503 T1 HRP20161503 T1 HR P20161503T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl ester
- cddo
- cddo methyl
- ester according
- powder
- Prior art date
Links
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 title claims 9
- TXGZJQLMVSIZEI-UQMAOPSPSA-N Bardoxolone Chemical compound C1=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5[C@H]4C(=O)C=C3[C@]21C TXGZJQLMVSIZEI-UQMAOPSPSA-N 0.000 claims 3
- 150000004702 methyl esters Chemical class 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Glass Compositions (AREA)
Claims (10)
1. Anhidridni kristalni metil 2-ciano-3,12-dioksolean-1,9(11)-dien-28-oat (CDDO metilnog estera), naznačen time da rendgenski difraktogram praha ima pikove na 8,78° 2θ , 12,94° 2θ, 13,35° 2θ, 14,18° 2θ i 17,4° 2θ±0,2° 2θ na temelju podataka prikupljenih na difraktometru s radijacijom Cu Kα.
2. CDDO metilnog estera prema zahtjevu 1, naznačen time da je rendgenski difraktogram praha uglavnom isti kako je prikazano na Slici 18.
3. CDDO metilnog estera prema zahtjevu 1, nadalje naznačen time da njegova krivulja diferencijalnog skeniranja kalorimetrom čini osnovni pomak na otprilike 157°C te endotermni maksimum na oko 224°C.
4. CDDO metilnog estera prema zahtjevu 3, naznačen time da je krivulja diferencijalnog skeniranja kalorimetrom uglavnom kako je prikazana na Slici 3.
5. Farmaceutski pripravak naznačen time da sadrži terapeutski učinkovitu količinu CDDO metilnog estera prema zahtjevu 1 i jedan ili više krutih farmaceutski prihvatljivih nosača.
6. Farmaceutski pripravak prema zahtjevu 5, naznačen time da je CDDO metilnog estera mikroniziran te su kruti farmaceutski prihvatljivi nosači jestivi nosači.
7. CDDO metilnog estera prema zahtjevu 1 naznačen time da je za uporabu u liječenju kroničnog upalnog stanja kod pacijenata koji pate od istog.
8. Kristalni CDDO metilnog estera hemibenzenata, naznačen time da njegov rendgenski difraktogram praha ima pikove na 9,25° 2θ, 14,17° 2θ , 14,62° 2θ, 16,32° 2θ i 17,11° 2θ±0,2° 2θ na temelju podataka prikupljenih na difraktometru s radijacijom Cu Kα.
9. Kristalni CDDO metilnog estera hemibenzenata prema zahtjevu 8, nadalje naznačen time da je krivulja diferencijalnog skeniranja kalorimetrom uglavnom kako je prikazana na Slici 23.
10. Kruti oblik CDDO metilnog estera naznačen time da je pripremljen postupkom koji čini korak kriobrušenja CDDO metilnog estera prema zahtjevu 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95593907P | 2007-08-15 | 2007-08-15 | |
| EP12153605.6A EP2450057B1 (en) | 2007-08-15 | 2008-08-14 | Novel forms of CDDO methyl ester |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161503T1 true HRP20161503T1 (hr) | 2017-01-13 |
Family
ID=40351005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120350AT HRP20120350T1 (hr) | 2007-08-15 | 2012-04-18 | Novi oblici cddo metilnog estera |
| HRP20161503TT HRP20161503T1 (hr) | 2007-08-15 | 2016-11-15 | Novi oblici cddo metilnog estera |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120350AT HRP20120350T1 (hr) | 2007-08-15 | 2012-04-18 | Novi oblici cddo metilnog estera |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8088824B2 (hr) |
| EP (2) | EP2450057B1 (hr) |
| JP (4) | JP5005812B2 (hr) |
| KR (2) | KR101544766B1 (hr) |
| CN (2) | CN101820758B (hr) |
| AR (2) | AR073155A1 (hr) |
| AT (1) | ATE549035T1 (hr) |
| AU (1) | AU2008287388B2 (hr) |
| BR (1) | BRPI0815540A8 (hr) |
| CA (2) | CA2696330C (hr) |
| CL (1) | CL2008002417A1 (hr) |
| CY (2) | CY1112864T1 (hr) |
| DK (2) | DK2450057T3 (hr) |
| EA (2) | EA023550B1 (hr) |
| ES (2) | ES2382571T3 (hr) |
| HK (1) | HK1143537A1 (hr) |
| HR (2) | HRP20120350T1 (hr) |
| HU (1) | HUE031866T2 (hr) |
| IL (2) | IL203824A (hr) |
| LT (1) | LT2450057T (hr) |
| MX (1) | MX2010001628A (hr) |
| NZ (1) | NZ583269A (hr) |
| PL (2) | PL2187741T3 (hr) |
| PT (2) | PT2187741E (hr) |
| SG (2) | SG10201504650VA (hr) |
| SI (2) | SI2450057T1 (hr) |
| TW (2) | TWI419899B (hr) |
| WO (1) | WO2009023232A1 (hr) |
| ZA (1) | ZA201001066B (hr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| CA2472581C (en) | 2002-01-15 | 2012-06-26 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| CA2670099A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| WO2008064132A2 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
| US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| TW200942231A (en) * | 2008-01-11 | 2009-10-16 | Reata Pharmaceuticals Inc | Synthetic triterpenoids and methods of use in the treatment of disease |
| TW201004627A (en) | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| CN104250280A (zh) | 2008-04-18 | 2014-12-31 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物 |
| JP5564490B2 (ja) | 2008-04-18 | 2014-07-30 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗炎症性ファルマコアを含む化合物および使用法 |
| NZ588710A (en) | 2008-04-18 | 2012-12-21 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| WO2009129545A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| JP5758801B2 (ja) | 2008-07-22 | 2015-08-05 | トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ | 単環式シアノエノンおよびその使用方法説明 |
| PT3254675T (pt) | 2009-02-13 | 2019-06-14 | Reata Pharmaceuticals Inc | Composições de dosagem oral de libertação prolongada que contêm cddo-me amorfo |
| EP2536285B1 (en) | 2010-02-18 | 2018-04-25 | vTv Therapeutics LLC | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| CA2795320C (en) | 2010-04-12 | 2019-01-22 | Reata Pharmaceuticals, Inc. | Method of treating obesity using antioxidant inflammation modulators |
| NZ612788A (en) | 2010-12-17 | 2015-10-30 | Reata Pharmaceuticals Inc | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| LT2683731T (lt) | 2011-03-11 | 2019-07-10 | Reata Pharmaceuticals, Inc. | C4-monometiltriterpenoido dariniai ir jų panaudojimo būdai |
| CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
| RS61544B1 (sr) * | 2012-04-27 | 2021-04-29 | Reata Pharmaceuticals Inc | Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| EP2892910B1 (en) * | 2012-09-10 | 2016-09-07 | AbbVie Inc. | Glycyrrhetinic acid derivatives with anti-inflammatory activity |
| TWI630212B (zh) | 2012-09-10 | 2018-07-21 | 瑞塔醫藥有限責任公司 | 丁香油素（ｏｌｅａｎｏｌｉｃ ａｃｉｄ）之ｃ１７－烷二基與烯二基衍生物及其使用方法 |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| EP2739639A4 (en) | 2012-09-28 | 2014-11-05 | Applied Pharmaceutical Science Inc | POLYMORPHS OF CDDO ETHYL ESTER AND USES THEREOF |
| CN102887936A (zh) * | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
| CN102875634B (zh) * | 2012-10-24 | 2014-08-20 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 |
| WO2014148455A1 (ja) | 2013-03-19 | 2014-09-25 | 第一三共株式会社 | テルペノイド誘導体 |
| UY35534A (es) | 2013-04-24 | 2014-10-31 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
| AU2014308600B2 (en) | 2013-08-23 | 2020-03-05 | Reata Pharmaceuticals Holdings, LLC | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
| US9896475B2 (en) | 2014-08-26 | 2018-02-20 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
| US10189791B2 (en) | 2014-08-26 | 2019-01-29 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
| WO2016039359A1 (ja) | 2014-09-10 | 2016-03-17 | 第一三共株式会社 | 眼疾患治療用及び予防用徐放性医薬組成物 |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| EP3233813B1 (en) | 2014-12-19 | 2022-02-02 | Geistlich Pharma AG | Processes for preparing oxathiazin-like compounds |
| US11591302B2 (en) | 2014-12-19 | 2023-02-28 | Geistlich Pharm A Ag | Processes for preparing oxathiazin-like compounds |
| WO2016130927A1 (en) | 2015-02-12 | 2016-08-18 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
| KR102688052B1 (ko) | 2015-07-02 | 2024-07-25 | 아세르타 파마. 비.브이. | (S)-4-(8-아미노-3-(1-(부트-2-이노일)피롤리딘-2-일)이미다조[1,5-a]피라진-1-일)-N-(피리딘-2-일)벤즈아마이드의 고체 형태 및 제제 |
| CN108290922B (zh) | 2015-09-23 | 2021-12-07 | 里亚塔医药公司 | 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 |
| EP3538104A1 (en) * | 2016-11-08 | 2019-09-18 | Reata Pharmaceuticals, Inc. | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| US11427533B2 (en) | 2017-07-13 | 2022-08-30 | Pliva Hrvatska D.O.O. | Crystalline polymorphs of bardoxolone methyl |
| ES2967689T3 (es) | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| WO2019241796A1 (en) | 2018-06-15 | 2019-12-19 | Reata Pharmaceuticals, Inc. | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| JPWO2020111089A1 (ja) | 2018-11-27 | 2021-10-14 | 協和キリン株式会社 | 医薬組成物 |
| JP2023526567A (ja) | 2020-05-09 | 2023-06-21 | リアタ ファーマシューティカルズ ホールディングス リミテッド ライアビリティ カンパニー | バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法 |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| EP4259155A1 (en) | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1317599C (en) * | 1986-03-26 | 1993-05-11 | Yukio Nezu | 1,2,6-triphenyl-4(1h)-pyridinone derivatives, production and uses thereof |
| JPH01273020A (ja) * | 1988-04-26 | 1989-10-31 | Toray Ind Inc | 有機非線形光学材料 |
| US5064823A (en) * | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| JP2876144B2 (ja) * | 1990-03-23 | 1999-03-31 | 東洋フアルマー株式会社 | ３―フェニルクマリン―７―イルオキシ酢酸誘導体とその製法及び用途 |
| GB9622173D0 (en) * | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
| US20050276836A1 (en) * | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6890946B2 (en) * | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
| AU2002243246A1 (en) * | 2000-11-28 | 2002-06-24 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| US6974801B2 (en) * | 2002-05-13 | 2005-12-13 | The Trustees Of Dartmounth College | Inhibitors and methods of use thereof |
| JP3618341B2 (ja) * | 2003-04-15 | 2005-02-09 | 山之内製薬株式会社 | 臭化物及びその結晶 |
| FR2861299B1 (fr) * | 2003-10-28 | 2006-01-27 | Pf Medicament | Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes |
| US7652654B2 (en) | 2003-12-08 | 2010-01-26 | Sony Corporation | Liquid crystal display and backlight adjusting method |
| US20060167097A1 (en) * | 2004-04-16 | 2006-07-27 | Cheppail Ramachandran | Compositions and uses of Amooranin compounds |
| CA2609353C (en) * | 2005-05-23 | 2015-04-28 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
| WO2007069895A1 (en) | 2005-12-12 | 2007-06-21 | Mosamedix B.V. | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
| US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
-
2008
- 2008-08-13 US US12/191,176 patent/US8088824B2/en active Active
- 2008-08-14 PL PL08795303T patent/PL2187741T3/pl unknown
- 2008-08-14 SG SG10201504650VA patent/SG10201504650VA/en unknown
- 2008-08-14 AR ARP080103557A patent/AR073155A1/es unknown
- 2008-08-14 CL CL2008002417A patent/CL2008002417A1/es unknown
- 2008-08-14 CN CN2008801112346A patent/CN101820758B/zh active Active
- 2008-08-14 CA CA2696330A patent/CA2696330C/en active Active
- 2008-08-14 EA EA201370109A patent/EA023550B1/ru unknown
- 2008-08-14 HU HUE12153605A patent/HUE031866T2/en unknown
- 2008-08-14 ES ES08795303T patent/ES2382571T3/es active Active
- 2008-08-14 BR BRPI0815540A patent/BRPI0815540A8/pt not_active Application Discontinuation
- 2008-08-14 LT LTEP12153605.6T patent/LT2450057T/lt unknown
- 2008-08-14 PT PT08795303T patent/PT2187741E/pt unknown
- 2008-08-14 TW TW097130947A patent/TWI419899B/zh active
- 2008-08-14 EP EP12153605.6A patent/EP2450057B1/en active Active
- 2008-08-14 KR KR1020147002848A patent/KR101544766B1/ko active IP Right Grant
- 2008-08-14 SI SI200831728A patent/SI2450057T1/sl unknown
- 2008-08-14 ES ES12153605.6T patent/ES2602978T3/es active Active
- 2008-08-14 DK DK12153605.6T patent/DK2450057T3/en active
- 2008-08-14 DK DK08795303.0T patent/DK2187741T3/da active
- 2008-08-14 AU AU2008287388A patent/AU2008287388B2/en active Active
- 2008-08-14 KR KR1020107005094A patent/KR101481764B1/ko active IP Right Grant
- 2008-08-14 AT AT08795303T patent/ATE549035T1/de active
- 2008-08-14 SI SI200830650T patent/SI2187741T1/sl unknown
- 2008-08-14 TW TW102134576A patent/TWI486357B/zh active
- 2008-08-14 NZ NZ583269A patent/NZ583269A/en unknown
- 2008-08-14 SG SG2011094158A patent/SG177905A1/en unknown
- 2008-08-14 PL PL12153605T patent/PL2450057T3/pl unknown
- 2008-08-14 MX MX2010001628A patent/MX2010001628A/es active IP Right Grant
- 2008-08-14 EP EP08795303A patent/EP2187741B1/en active Active
- 2008-08-14 CA CA2871864A patent/CA2871864C/en active Active
- 2008-08-14 CN CN201310016448.8A patent/CN103254267B/zh active Active
- 2008-08-14 JP JP2010521031A patent/JP5005812B2/ja active Active
- 2008-08-14 WO PCT/US2008/009703 patent/WO2009023232A1/en active Application Filing
- 2008-08-14 PT PT121536056T patent/PT2450057T/pt unknown
- 2008-08-14 EA EA201070149A patent/EA018704B1/ru unknown
-
2010
- 2010-02-09 IL IL203824A patent/IL203824A/en active IP Right Grant
- 2010-02-12 ZA ZA201001066A patent/ZA201001066B/xx unknown
- 2010-10-25 HK HK10110040.7A patent/HK1143537A1/xx unknown
-
2011
- 2011-11-29 US US13/306,043 patent/US8309601B2/en active Active
-
2012
- 2012-04-18 HR HRP20120350AT patent/HRP20120350T1/hr unknown
- 2012-05-23 JP JP2012117773A patent/JP2012188438A/ja active Pending
- 2012-06-13 CY CY20121100542T patent/CY1112864T1/el unknown
- 2012-06-29 US US13/537,583 patent/US8633243B2/en active Active
-
2015
- 2015-05-07 JP JP2015094538A patent/JP2015164939A/ja active Pending
-
2016
- 2016-11-15 HR HRP20161503TT patent/HRP20161503T1/hr unknown
- 2016-11-23 CY CY20161101205T patent/CY1118329T1/el unknown
-
2017
- 2017-03-27 IL IL251419A patent/IL251419A0/en unknown
- 2017-08-10 JP JP2017154939A patent/JP2018009001A/ja active Pending
-
2020
- 2020-03-25 AR ARP200100825A patent/AR119704A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161503T1 (hr) | Novi oblici cddo metilnog estera | |
| RU2017130849A (ru) | Дейтерированная производная хенодезоксихолевой кислоты и фармацевтическая композиция, содержащая данное соединение | |
| HRP20180902T1 (hr) | Kristalni oblici modulatora receptora androgena | |
| Jiang et al. | Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes | |
| HRP20170241T2 (hr) | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline | |
| JP2010514807A5 (hr) | ||
| HRP20171587T1 (hr) | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola | |
| ME02701B (me) | Novi kristalni oblik vi agomelatina1 postupak priprave i farmaceutski pripravci istog | |
| MY189770A (en) | Biaryl derivative as gpr120 agonists | |
| JP2010514806A5 (hr) | ||
| JP2016511753A5 (hr) | ||
| UA83719C2 (ru) | Кристаллическая форма iii агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит | |
| Liu et al. | Synthesis and anti-tumor evaluation of panaxadiol derivatives | |
| EP2508523A3 (en) | Polymorphs of dasatinib and process for preparation thereof | |
| JP2021181446A5 (hr) | ||
| JP2014506907A5 (hr) | ||
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| JP2018537513A5 (hr) | ||
| JP2018527305A5 (hr) | ||
| MX2015016543A (es) | Derivados de biarilo como agonistas de gpr120. | |
| JO3434B1 (ar) | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري | |
| RU2017141763A (ru) | Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида | |
| JP2011506587A5 (hr) | ||
| HRP20200212T1 (hr) | Antagonisti kanabinoidnog receptora/inverzivni agonisti | |
| Wang et al. | Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents |